Clinical Cancer Research The Science of Cancer Health Disparities Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Clinical Cancer Research 14, 4463-4468, July 15, 2008. doi: 10.1158/1078-0432.CCR-07-5243
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Shields, A. F.
Right arrow Articles by Muzik, O.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shields, A. F.
Right arrow Articles by Muzik, O.

Imaging, Diagnosis, Prognosis

Analysis and Reproducibility of 3'-Deoxy-3'-[18F]Fluorothymidine Positron Emission Tomography Imaging in Patients with Non–Small Cell Lung Cancer

Anthony F. Shields1,2, Jawana M. Lawhorn-Crews1,2, David A. Briston1,2, Sajad Zalzala1,2, Shirish Gadgeel1,2, Kirk A. Douglas1,2, Thomas J. Mangner1,3, Lance K. Heilbrun1,2 and Otto Muzik1,4

Authors’ Affiliations: 1 Karmanos Cancer Institute and Departments of 2 Internal Medicine, 3 Radiology, and 4 Pediatrics, Wayne State University, Detroit, Michigan

Requests for reprints: Anthony F. Shields, Karmanos Cancer Institute, Wayne State University, 4100 John R. Street, 4 HWCRC, Detroit, MI 48201-2013. Phone: 313-576-8735; Fax: 313-576-8767; E-mail: ShieldsA{at}Karmanos.org.

Purpose: Imaging tumor proliferation with 3'-deoxy-3'-[18F]fluorothymidine (FLT) and positron emission tomography is being developed with the goal of monitoring antineoplastic therapy. This study assessed the methods to measure FLT retention in patients with non-small cell lung cancer (NSCLC) to measure the reproducibility of this approach.

Experimental Design: Nine patients with NSCLC who were untreated or had progressed after previous therapy were imaged twice using FLT and positron emission tomography within 2 to 7 days. Reproducibility (that is, error) was measured as the percent difference between the two patient scans. Dynamic imaging was obtained during the first 60 min after injection. Activity in the blood was assessed from aortic images and the fraction of unmetabolized FLT was measured. Regions of interest were drawn on the plane with the highest activity and the adjacent planes to measure standardized uptake value (SUVmean) and kinetic variables of FLT flux.

Results: We found that the SUVmean obtained from 30 to 60 min had a mean error of 3.6% (range, 0.6-6.9%; SD, 2.3%) and the first and second scans were highly correlated (r2 = 0.99; P < 0.0001). Using shorter imaging times from 25 to 30 min or from 55 to 60 min postinjection also resulted in small error rates; SUVmean mean errors were 8.4% and 5.7%, respectively. Compartmental and graphical kinetic analyses were also fairly reproducible (r2 = 0.59; P = 0.0152 and r2 = 0.58; P = 0.0175 respectively).

Conclusion: FLT imaging of patients with NSCLC was quite reproducible with a worst case SUVmean error of 21% when using a short imaging time.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.